scholarly journals Single intravitreal ranibizumab for myopic choroidal neovascularization

2011 ◽  
pp. 1079
Author(s):  
Zunaina Embong ◽  
Saidin Nor-Masniwati ◽  
Ismail Shatriah
Keyword(s):  
Choroidal Neovascularization ◽  
Intravitreal Ranibizumab ◽  
Myopic Choroidal Neovascularization

INTRAVITREAL RANIBIZUMAB VERSUS BEVACIZUMAB FOR TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION

Retina ◽  
2012 ◽  
Vol 32 (8) ◽  
pp. 1539-1546 ◽  
Author(s):  
Pierluigi Iacono ◽  
Maurizio Battaglia Parodi ◽  
Alessandro Papayannis ◽  
Stylianos Kontadakis ◽  
Saumil Sheth ◽  
...  
Keyword(s):  
Choroidal Neovascularization ◽  
Intravitreal Ranibizumab ◽  
Myopic Choroidal Neovascularization

scholarly journals Intravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularization

2008 ◽  
Vol 247 (3) ◽  
pp. 311-318 ◽  
Author(s):  
Lazaros Konstantinidis ◽  
Irmela Mantel ◽  
Jean-Antoine C. Pournaras ◽  
Leonidas Zografos ◽  
Aude Ambresin
Keyword(s):  
Choroidal Neovascularization ◽  
Intravitreal Ranibizumab ◽  
Myopic Choroidal Neovascularization

Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization

2017 ◽  
Vol 238 (4) ◽  
pp. 196-204 ◽  
Author(s):  
Cristina Calvo-González ◽  
Juan Reche-Frutos ◽  
José Ignacio Fernández-Vigo ◽  
Federico Sáenz-Francés ◽  
Cristina Fernández-Pérez ◽  
...  
Keyword(s):  
Choroidal Neovascularization ◽  
Long Term Outcomes ◽  
Intravitreal Ranibizumab ◽  
Myopic Choroidal Neovascularization ◽  
Dosing Regimens

A new treatment algorithm for the management of myopic choroidal neovascularization using intravitreal ranibizumab

2015 ◽  
Vol 93 (6) ◽  
pp. e519-e520 ◽  
Author(s):  
Pierluigi Iacono ◽  
Maurizio Battaglia Parodi ◽  
Alexandros Papayannis ◽  
Carlo La Spina ◽  
Monica Varano ◽  
...  
Keyword(s):  
Choroidal Neovascularization ◽  
Treatment Algorithm ◽  
Intravitreal Ranibizumab ◽  
Myopic Choroidal Neovascularization ◽  
New Treatment

INTRAVITREAL RANIBIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION

Retina ◽  
2010 ◽  
Vol 30 (3) ◽  
pp. 407-412 ◽  
Author(s):  
RUFINO M. SILVA ◽  
JOSÉ M. RUIZ-MORENO ◽  
PAULO ROSA ◽  
ÂNGELA CARNEIRO ◽  
JOÃO NASCIMENTO ◽  
...  
Keyword(s):  
Choroidal Neovascularization ◽  
Intravitreal Ranibizumab ◽  
Myopic Choroidal Neovascularization

scholarly journals Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study

2019 ◽  
Vol 2019 ◽  
pp. 1-6
Author(s):  
Burak Erden ◽  
Selim Bölükbaşı ◽  
Emine Baş ◽  
Akın Çakır
Keyword(s):  
Choroidal Neovascularization ◽  
Treatment Modalities ◽  
Intravitreal Ranibizumab ◽  
Myopic Choroidal Neovascularization ◽  
Significant Difference ◽  
Intravitreal Aflibercept ◽  
Before And After ◽  
The Mean ◽  
One Year ◽  
Retrospective Comparative Study

Purpose. To compare one-year treatment outcomes of intravitreal aflibercept (IVA) and intravitreal ranibizumab (IVR) for treatment of myopic choroidal neovascularization (mCNV). Methods. The medical records of a total of 30 eyes diagnosed with mCNV and underwent IVA or IVR treatment for a minimum one-year follow-up were studied retrospectively. All the subjects had an axial length >26 mm and received a 1 + PRN (pro re nata) regimen IVA or IVR. Best-corrected visual acuity (BCVA) and central macular thicknesses (CMT) on optical coherence tomography were evaluated before and after treatment. Results. There were 12 eyes in IVA group, with a mean age of 60.0 ± 10.2 years. The mean BCVA significantly improved from baseline 1.54 ± 0.76 to 0.85 ± 0.61 and the mean CMT significantly decreased from baseline 384.3 ± 119.1 μm to 305.9 ± 75.4 μm at Month 12 (p:0.024 and p:0.011, respectively). There were 18 eyes in IVR group, with a mean age of 57.4 ± 13.1 years. The mean BCVA improved from baseline 1.14 ± 0.90 to 1.04 ± 0.93 and the mean CMT significantly decreased from baseline 366.5 ± 102.3 μm to 323.6 ± 103.6 μm at Month 12 after IVR (p:0.345 and p:0.011, respectively). There was no significant difference between the groups in CMT changes in the study period (p:0.178), but IVA resulted in significantly better final visual gain (0.69 versus 0.09; p:0.006). Conclusions. Both IVA and IVR treatment modalities resulted in similar anatomical outcomes but IVA had better visual outcomes in treatment of mCNV.

SHORT-TERM EFFICACY AND SAFETY OF INTRAVITREAL RANIBIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION

Retina ◽  
2008 ◽  
Vol 28 (8) ◽  
pp. 1117-1123 ◽  
Author(s):  
RUFINO M. SILVA ◽  
JOSÉ M. RUIZ-MORENO ◽  
JOÃO NASCIMENTO ◽  
ÃNGELA CARNEIRO ◽  
PAULO ROSA ◽  
...  
Keyword(s):  
Choroidal Neovascularization ◽  
Efficacy And Safety ◽  
Short Term ◽  
Intravitreal Ranibizumab ◽  
Myopic Choroidal Neovascularization ◽  
Term Efficacy
Sign in / Sign up

Export Citation Format

Share Document